Our R&D portfolio primarily reflects our scientific, technical and clinical competencies in vector-borne infectious diseases and in both bacterial and viral vaccines.
Clinical Pipeline
Wir wollen das Leben der Menschen verändern, indem wir innovative und bahnbrechende Forschungsarbeit leisten, um potenziell durch Impfstoffe vermeidbare Krankheiten zu bekämpfen. Unsere klinische Entwicklungspipeline umfasst Impfstoffe gegen Infektionskrankheiten mit hohem ungedecktem Bedarf, für die derzeit keine Impfstoffe verfügbar sind.
Chikungunya – VLA1553
Chikungunya is a mosquito-borne viral infection spreading in the Americas and Europe caused by the chikungunya virus (CHIKV), a Togaviridae virus transmitted by Aedes mosquitoes. VLA1553 is a live-attenuated, single dose vaccine candidate targeting the chikungunya virus.
Mehr lesenLyme Borreliose – VLA15
Lyme disease is the most common vector-borne illness in the Northern Hemisphere. Valneva's candidate, partnered with Pfizer, is the only vaccine in clinical development worldwide. Valneva´s vaccine candidate VLA15, under Fast Track Designation by the FDA, is a multivalent vaccine that targets the outer surface protein A (OspA) of Borrelia.
Mehr lesenShigella – S4V2
Shigellosis, caused by Shigella bacteria, is the second leading cause of fatal diarrheal disease worldwide. S4V2 is the world’s most clinically advanced tetravalent Shigella vaccine candidate.
Mehr lesen